Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

• Hauptverfasser: Lourdes Farre (VerfasserIn), Gabriela Sanz (VerfasserIn), Neus Ruiz-Xivillé (VerfasserIn), Manuel Castro de Moura (VerfasserIn), Juan Francisco Martin-Tejera (VerfasserIn), Samuel Gonçalves-Ribeiro (VerfasserIn), Maria Martinez-Iniesta (VerfasserIn), Monica Calaf (VerfasserIn), Jose Luis Mosquera (VerfasserIn), José Ignacio Martín-Subero (VerfasserIn), Isabel Granada (VerfasserIn), Manel Esteller (VerfasserIn), Eva Domingo-Domenech (VerfasserIn), Fina Climent (VerfasserIn), Alberto Villanueva (VerfasserIn), Anna Sureda (VerfasserIn)
• Format: Buch
• Veröffentlicht: The Company of Biologists, 2021-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well-characterized preclinical models for...